Bioventus (BVS) Competitors $7.64 +0.56 (+7.91%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$7.64 0.00 (-0.07%) As of 08/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BVS vs. PRCT, LQDA, LMAT, AORT, EYE, ENOV, CNMD, NVCR, SSII, and CDREShould you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include PROCEPT BioRobotics (PRCT), Liquidia Technologies (LQDA), LeMaitre Vascular (LMAT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), NovoCure (NVCR), SS Innovations International (SSII), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. Bioventus vs. Its Competitors PROCEPT BioRobotics Liquidia Technologies LeMaitre Vascular Artivion National Vision Enovis CONMED NovoCure SS Innovations International Cadre PROCEPT BioRobotics (NASDAQ:PRCT) and Bioventus (NYSE:BVS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings. Which has more volatility and risk, PRCT or BVS? PROCEPT BioRobotics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Is PRCT or BVS more profitable? Bioventus has a net margin of -7.11% compared to PROCEPT BioRobotics' net margin of -30.60%. Bioventus' return on equity of 15.61% beat PROCEPT BioRobotics' return on equity.Company Net Margins Return on Equity Return on Assets PROCEPT BioRobotics-30.60% -23.73% -17.34% Bioventus -7.11%15.61%4.01% Does the media favor PRCT or BVS? In the previous week, PROCEPT BioRobotics had 11 more articles in the media than Bioventus. MarketBeat recorded 11 mentions for PROCEPT BioRobotics and 0 mentions for Bioventus. PROCEPT BioRobotics' average media sentiment score of 1.16 beat Bioventus' score of 0.00 indicating that PROCEPT BioRobotics is being referred to more favorably in the media. Company Overall Sentiment PROCEPT BioRobotics Positive Bioventus Neutral Do insiders & institutionals believe in PRCT or BVS? 89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 6.6% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger valuation and earnings, PRCT or BVS? PROCEPT BioRobotics has higher earnings, but lower revenue than Bioventus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPROCEPT BioRobotics$224.50M10.22-$91.41M-$1.55-26.60Bioventus$564.14M1.12-$156.23MN/AN/A Do analysts recommend PRCT or BVS? PROCEPT BioRobotics currently has a consensus price target of $74.88, indicating a potential upside of 81.60%. Bioventus has a consensus price target of $13.75, indicating a potential upside of 79.97%. Given PROCEPT BioRobotics' stronger consensus rating and higher probable upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than Bioventus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PROCEPT BioRobotics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Bioventus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryPROCEPT BioRobotics beats Bioventus on 9 of the 15 factors compared between the two stocks. Get Bioventus News Delivered to You Automatically Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BVS vs. The Competition Export to ExcelMetricBioventusSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$631.67M$85.46M$5.76B$20.92BDividend YieldN/AN/A4.41%3.58%P/E Ratio-12.5211.0031.1029.13Price / Sales1.12105.21433.2253.00Price / Cash12.5818.4137.7323.54Price / Book2.737.139.535.45Net Income-$156.23M-$26.48M$3.26B$992.10M7 Day Performance3.66%-1.01%2.10%2.61%1 Month Performance18.08%-3.56%2.81%1.46%1 Year Performance-22.98%57.70%30.56%10.72% Bioventus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BVSBioventusN/A$7.64+7.9%$13.75+80.0%-22.7%$631.67M$564.14M-12.521,200PRCTPROCEPT BioRobotics3.57 of 5 stars$40.71-2.1%$74.88+83.9%-48.6%$2.31B$224.50M-26.26430LQDALiquidia Technologies3.5433 of 5 stars$27.72+6.8%$31.40+13.3%+178.7%$2.23B$14M-16.3150LMATLeMaitre Vascular2.2402 of 5 stars$95.04-0.9%$98.00+3.1%+16.4%$2.17B$219.86M46.14490Positive NewsAORTArtivion3.5705 of 5 stars$42.810.0%$39.80-7.0%+75.6%$2.02B$388.54M-101.921,600Analyst ForecastInsider TradeEYENational Vision2.8254 of 5 stars$23.87+5.0%$24.73+3.6%+142.5%$1.80B$1.82B-132.6113,411Positive NewsENOVEnovis4.4882 of 5 stars$29.51-0.1%$51.00+72.8%-28.7%$1.69B$2.11B-2.077,367CNMDCONMED3.9727 of 5 stars$53.35+0.4%$59.80+12.1%-18.0%$1.64B$1.31B15.113,900News CoveragePositive NewsNVCRNovoCure4.1243 of 5 stars$12.09+3.1%$28.79+138.1%-26.8%$1.31B$605.22M-7.751,488News CoveragePositive NewsSSIISS Innovations InternationalN/A$6.55-2.1%N/AN/A$1.30B$20.65M0.004CDRECadre1.9753 of 5 stars$29.66+1.4%$31.50+6.2%-11.5%$1.19B$567.56M31.552,284 Related Companies and Tools Related Companies PROCEPT BioRobotics Alternatives Liquidia Technologies Alternatives LeMaitre Vascular Alternatives Artivion Alternatives National Vision Alternatives Enovis Alternatives CONMED Alternatives NovoCure Alternatives SS Innovations International Alternatives Cadre Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BVS) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access